Home > Publications Database > Proteolytically generated soluble Tweak Receptor Fn14 is a blood biomarker for γ-secretase activity. > print

001     165254
005     20230915090613.0
024 7 _ |a pmc:PMC9549706
|2 pmc
024 7 _ |a 10.15252/emmm.202216084
|2 doi
024 7 _ |a pmid:36069059
|2 pmid
024 7 _ |a 1715-4684
|2 ISSN
024 7 _ |a 1757-4676
|2 ISSN
024 7 _ |a 1757-4684
|2 ISSN
024 7 _ |a altmetric:135631498
|2 altmetric
037 _ _ |a DZNE-2022-01547
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Güner, Gökhan
|0 P:(DE-2719)2812025
|b 0
|e First author
245 _ _ |a Proteolytically generated soluble Tweak Receptor Fn14 is a blood biomarker for γ-secretase activity.
260 _ _ |a Heidelberg
|c 2022
|b EMBO Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1670592930_11876
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a CC BY: https://creativecommons.org/licenses/by/4.0/
520 _ _ |a Fn14 is a cell surface receptor with key functions in tissue homeostasis and injury but is also linked to chronic diseases. Despite its physiological and medical importance, the regulation of Fn14 signaling and turnover is only partly understood. Here, we demonstrate that Fn14 is cleaved within its transmembrane domain by the protease γ-secretase, resulting in secretion of the soluble Fn14 ectodomain (sFn14). Inhibition of γ-secretase in tumor cells reduced sFn14 secretion, increased full-length Fn14 at the cell surface, and enhanced TWEAK ligand-stimulated Fn14 signaling through the NFκB pathway, which led to enhanced release of the cytokine tumor necrosis factor. γ-Secretase-dependent sFn14 release was also detected ex vivo in primary tumor cells from glioblastoma patients, in mouse and human plasma and was strongly reduced in blood from human cancer patients dosed with a γ-secretase inhibitor prior to chimeric antigen receptor (CAR)-T-cell treatment. Taken together, our study demonstrates a novel function for γ-secretase in attenuating TWEAK/Fn14 signaling and suggests the use of sFn14 as an easily measurable pharmacodynamic biomarker to monitor γ-secretase activity in vivo.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer's disease
|2 Other
650 _ 7 |a TNR12
|2 Other
650 _ 7 |a ectodomain shedding
|2 Other
650 _ 7 |a glioblastoma
|2 Other
650 _ 7 |a intramembrane proteolysis
|2 Other
650 _ 2 |a Amyloid Precursor Protein Secretases
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Biomarkers
|2 MeSH
650 _ 2 |a Cytokine TWEAK
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Ligands
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Receptors, Cell Surface: metabolism
|2 MeSH
650 _ 2 |a Receptors, Chimeric Antigen
|2 MeSH
650 _ 2 |a Receptors, Tumor Necrosis Factor: metabolism
|2 MeSH
650 _ 2 |a TWEAK Receptor
|2 MeSH
650 _ 2 |a Tumor Necrosis Factor-alpha
|2 MeSH
700 1 _ |a Assfalg, Marlene
|0 P:(DE-2719)9001720
|b 1
700 1 _ |a Zhao, Kai
|b 2
700 1 _ |a Dreyer, Tobias
|b 3
700 1 _ |a Lahiri, Shibojyoti
|b 4
700 1 _ |a Lo, Yun
|b 5
700 1 _ |a Slivinschi, Bianca
|0 P:(DE-2719)9002486
|b 6
|u dzne
700 1 _ |a Imhof, Axel
|0 0000-0003-2993-8249
|b 7
700 1 _ |a Jocher, Georg
|0 P:(DE-2719)2813355
|b 8
700 1 _ |a Strohm, Laura
|0 P:(DE-2719)2812236
|b 9
700 1 _ |a Behrends, Christian
|0 0000-0002-9184-7607
|b 10
700 1 _ |a Langosch, Dieter
|0 P:(DE-2719)9001125
|b 11
700 1 _ |a Bronger, Holger
|0 0000-0002-3706-6738
|b 12
700 1 _ |a Nimsky, Christopher
|0 0000-0002-8216-9410
|b 13
700 1 _ |a Bartsch, Jörg W
|0 0000-0002-2773-3357
|b 14
700 1 _ |a Riddell, Stanley R
|b 15
700 1 _ |a Steiner, Harald
|0 P:(DE-2719)2000023
|b 16
700 1 _ |a Lichtenthaler, Stefan
|0 P:(DE-2719)2181459
|b 17
|e Last author
773 _ _ |a 10.15252/emmm.202216084
|g Vol. 14, no. 10
|0 PERI:(DE-600)2485479-7
|n 10
|p e16084
|t EMBO molecular medicine
|v 14
|y 2022
|x 1715-4684
856 4 _ |u https://pub.dzne.de/record/165254/files/DZNE-2022-01547.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/165254/files/DZNE-2022-01547.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:165254
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2812025
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9001720
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)9002486
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2813355
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 9
|6 P:(DE-2719)2812236
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 11
|6 P:(DE-2719)9001125
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 16
|6 P:(DE-2719)2000023
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)2181459
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-04
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-04
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-02-04
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-07-19T13:19:31Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-07-19T13:19:31Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review, Double blind peer review
|d 2021-07-19T13:19:31Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-29
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EMBO MOL MED : 2021
|d 2022-11-29
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b EMBO MOL MED : 2021
|d 2022-11-29
920 1 _ |0 I:(DE-2719)1110006
|k AG Lichtenthaler
|l Neuroproteomics
|x 0
920 1 _ |0 I:(DE-2719)1110000-1
|k AG Steiner
|l Biochemistry of γ-Secretase
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1110006
980 _ _ |a I:(DE-2719)1110000-1
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21